Drug intelligence / Profile preview

pelareorep + atezolizumab + TAS-102

Development stage: Unknown
Lead developer: Roche
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Pelareorep + atezolizumab + TAS-102 is an investigational combination regimen consisting of pelareorep (an intravenously delivered oncolytic reovirus), atezolizumab (an anti-PD-L1 monoclonal antibody), and TAS-102 (trifluridine/tipiracil, a nucleoside analog-based chemotherapy). Pelareorep selectively replicates in and lyses cancer cells, releasing tumor antigens and promoting an inflamed tumor microenvironment with increased PD-L1 expression and T-cell infiltration. This immunologically active state synergizes with atezolizumab, which blocks PD-L1 to restore T-cell-mediated anti-tumor activity, while TAS-102 directly inhibits tumor cell proliferation by inducing DNA damage.

Other names: Reolysin + atezolizumab + LonsurfReolysin + atezolizumab + TAS-102Reolysin + atezolizumab + trifluridine and tipiracilReolysin + atezolizumab + trifluridine/tipiracilReolysin + Tecentriq + LonsurfReolysin + Tecentriq + TAS-102Reolysin + Tecentriq + trifluridine and tipiracilReolysin + Tecentriq + trifluridine/tipiracilpelareorep + atezolizumab + Lonsurfpelareorep + atezolizumab + trifluridine and tipiracilpelareorep + atezolizumab + trifluridine/tipiracilpelareorep + Tecentriq + Lonsurfpelareorep + Tecentriq + TAS-102pelareorep + Tecentriq + trifluridine and tipiracilpelareorep + Tecentriq + trifluridine/tipiracil

Targets

CD80 (T-lymphocyte activation antigen CD80)DNAJAM-A (Junctional adhesion molecule A)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TYMP (Thymidine phosphorylase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on pelareorep + atezolizumab + TAS-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pelareorep + atezolizumab + TAS-102.